Phase 1/2 Study of the Oral TRK Inhibitor LOXO-101 in Pediatric Patients with Advanced Sold or Primary Central Nervous System Tumors
In this study, children and adolescents aged 1 to 21 years with an advanced or metastatic solid tumor - a primary tumor of the central nervous system or IFS (infantile fibrosarcoma) - are treated with LOXO-101 (Larotrectinib). Larotrectinib specifically inhibits tropomyosin receptor kinases (TRK), a group of signaling proteins that play an important role in cellular communication and tumor growth. The study therefore treats tumors whose genetic information has changed in this area (NTRK fusion) and where the tumor has recurred or progressed after standard therapy. Larotrectinib is taken orally over a 28-day cycle.